Leerink Partnrs Has Positive Outlook of ARCT FY2025 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Leerink Partnrs raised their FY2025 EPS estimates for shares of Arcturus Therapeutics in a note issued to investors on Wednesday, November 12th. Leerink Partnrs analyst L. Nsongo now forecasts that the biotechnology company will post earnings per share of ($2.52) for the year, up from their previous forecast of ($3.95). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. Leerink Partnrs also issued estimates for Arcturus Therapeutics’ Q4 2025 earnings at ($1.18) EPS and FY2026 earnings at ($4.12) EPS.

ARCT has been the topic of several other reports. Wall Street Zen raised Arcturus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. BTIG Research lowered their price objective on Arcturus Therapeutics from $48.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, October 22nd. Leerink Partners cut their price objective on Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating on the stock in a research note on Friday, August 22nd. Wells Fargo & Company decreased their target price on shares of Arcturus Therapeutics from $42.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, October 23rd. Finally, HC Wainwright lowered their price target on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Arcturus Therapeutics has an average rating of “Moderate Buy” and an average target price of $36.00.

Arcturus Therapeutics Stock Down 7.0%

Shares of Arcturus Therapeutics stock opened at $6.76 on Monday. The stock has a market cap of $192.05 million, a price-to-earnings ratio of -2.75 and a beta of 2.47. Arcturus Therapeutics has a twelve month low of $6.72 and a twelve month high of $24.17. The company’s fifty day moving average is $15.96 and its 200 day moving average is $14.56.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.60. The firm had revenue of $17.15 million during the quarter, compared to analysts’ expectations of $17.47 million. Arcturus Therapeutics had a negative net margin of 68.35% and a negative return on equity of 28.68%.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ARCT. Osaic Holdings Inc. grew its position in shares of Arcturus Therapeutics by 51.8% during the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after buying an additional 738 shares during the period. US Bancorp DE boosted its stake in Arcturus Therapeutics by 218.9% during the first quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,329 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Arcturus Therapeutics by 163.4% in the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 2,586 shares during the period. Compagnie Lombard Odier SCmA bought a new stake in Arcturus Therapeutics in the third quarter valued at $111,000. Finally, CANADA LIFE ASSURANCE Co increased its stake in Arcturus Therapeutics by 27.5% in the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 1,567 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.